RET C634W
|
Thyroid Gland Carcinoma
|
RET C634W
|
Thyroid Gland Carcinoma
|
regorafenib Sensitive: D – Preclinical
|
regorafenib Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RAF265 Sensitive: D – Preclinical
|
RAF265 Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
AMG 706 Resistant: D – Preclinical
|
AMG 706 Resistant: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
lenvatinib Sensitive: D – Preclinical
|
lenvatinib Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Carcinoma
|
RET C634W
|
Thyroid Gland Carcinoma
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
RET C634W
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: D – Preclinical
|
cabozantinib capsule Sensitive: D – Preclinical
|
RET C634W
|
Thyroid Gland Papillary Carcinoma
|
RET C634W
|
Thyroid Gland Papillary Carcinoma
|
AZD1480 Sensitive: D – Preclinical
|
AZD1480 Sensitive: D – Preclinical
|